Atrasentan for metastatic hormone refractory prostate cancer
Murphy G
Record ID 32006000009
English, French
Authors' objectives:
The aim of this report is to summarize the available information on the use of atrasentan (Trade Mark Xinlay, manufactured by Abbott Laboratories) for the treatment of metastatic hormone refractory prostate cancer.
Authors' recommendations:
An anti-cancer drug from a new class of agents called selective endothelin-A receptor antagonists, this drug is being studied in a subset of patients with advanced prostate cancer.
Phase II and III studies evaluating time to clinical and radiographic progression failed to demonstrate a significant benefit with atrasentan versus placebo.
The adverse effects, observed more frequently in those treated with atrasentan than in placebo-treated patients, included peripheral edema, rhinitis, headache, infection, dyspnea, and heart failure.
Atrasentan's role in the various stages of advanced prostate cancer, and relative to the chemotherapeutic agent docetaxel, has not been determined.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
https://www.ccohta.ca/
Year Published:
2005
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Antineoplastic Agents
- Prostatic Neoplasms
Contact
Organisation Name:
Canadian Coordinating Office for Health Technology Assessment
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.